Allergan Inc. said Monday it expects to receive antitrust approval for its acquisition of Inamed Corp. this week.
Approval for Allergan’s $3.2 billion buyout of Inamed has taken longer than expected.
The company has extended its buyout offer several times, including again today. Allergan, which makes eye and skin drugs, now expects to close the deal on Friday.
Santa Barbara-based Inamed makes breast implants, obesity treatments and face fillers.
The companies are working with the Federal Trade Commission to complete Inamed’s sale of Reloxin. The treatment is a potential competitor to Allergan’s flagship Botox wrinkle-fighting drug.
In an earlier interview, Allergan Chief Executive David E.I. Pyott said Inamed would return the rights to Reloxin to France’s Beaufor Ipsen SA, which developed the treatment.
